logo-loader
viewAkari Therapeutics

Akari Therapeutics expects readouts from two key Phase II studies by year-end

Clive Richardson, chief executive of Akari Therapeutics PLC (NASDAQ:AKTX), introduces the business to Proactive London and outlines some of the work they're doing in the area of acute and chronic inflammation.

Discussing their protein Nomacopan, he says it's currently being clinically evaluated in four indications including a severe blistering skin disease and a sight threatening surface of the eye condition.

Quick facts: Akari Therapeutics

Price: 1.81 USD

NASDAQ:AKTX
Market: NASDAQ
Market Cap: $38.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Iofina PLC's Tom Becker updates on Organic Vines investment and IO#8...

Iofina PLC's (LON:IOF) Tom Becker speaks to Proactive London's Andrew Scott soon after announcing their investment in Organic Vines - a hemp seed production and genetics firm. Becker says they're anticipating to turn a profit of US$1.8mln by mid-2020. He also updates on the construction of...

11 hours, 3 minutes ago

2 min read